None
SEDAR Interim Financial Statements
RVV · Price
[
{
"companyName": "Revive Therapeutics Ltd.",
"reportingPeriodEnd": "2025-12-31",
"reportStatus": "Unaudited",
"auditorName": null,
"auditorKeyMatters": [],
"balanceSheet": {
"cashAndCashEquivalents": 12883,
"restrictedCash": 10000,
"hstReceivable": 39415,
"prepaidExpenses": 66585,
"totalCurrentAssets": 128883,
"investments": 131762,
"equipment": 734,
"totalNonCurrentAssets": 132496,
"totalAssets": 261379,
"accountsPayableAndAccruedLiabilities": 3851981,
"totalCurrentLiabilities": 3851981,
"statuteBarredLiabilities": 79941,
"promissoryNote": 69488,
"totalLiabilities": 4001410,
"shareCapital": 47857583,
"warrantsAndBrokerAndFinderWarrants": 2434776,
"contributedSurplus": 23685704,
"accumulatedDeficit": -77718094,
"totalShareholdersEquity": -3740031,
"totalLiabilitiesAndShareholdersEquity": 261379,
"cashPerShare": 0.0000,
"workingCapitalPerShare": -0.0085
},
"incomeStatement": {
"researchCosts": 0,
"stockBasedCompensation": 19945,
"officeExpenses": 79032,
"consultingFees": 325444,
"professionalFees": 78913,
"foreignExchangeGainLoss": 13305,
"depreciationAndAmortization": 94,
"comprehensiveLossBeforeItems": 516733,
"amortizationOfLeaseLiability": 0,
"gainOnSettlementOfDebt": -73850,
"interestIncome": -1360,
"financeIncomeOnSubLease": -76,
"unrealizedLossOfInvestments": 4020,
"comprehensiveLossForThePeriod": -520476,
"comprehensiveLossPerShareBasicAndDiluted": 0,
"weightedAverageCommonSharesOutstandingBasicAndDiluted": 432488880
},
"cashFlowStatement": {
"comprehensiveLossForThePeriod": -520476,
"depreciationAndAmortization": 94,
"stockBasedCompensation": 19945,
"sharesIssuedForConsultingFees": 67400,
"interestOnPromissoryNote": 2621,
"accretionOfLeaseLiability": 0,
"financeIncomeOnSubLease": -76,
"unrealizedLossOfInvestments": 4020,
"foreignExchangeLossGain": 279,
"hstReceivable": -39415,
"prepaidExpenses": -22732,
"restrictedCash": 0,
"accountsPayableAndAccruedLiabilities": 337787,
"netCashAndCashEquivalentsUsedInOperatingActivities": -150477,
"purchaseOfInvestment": -30000,
"netCashAndCashEquivalentsUsedInInvestingActivities": -30000,
"proceedsFromPrivatePlacementsNetOfCosts": 148800,
"leasePayments": -25848,
"proceedsFromSublease": 25848,
"netCashAndCashEquivalentsProvidedByFinancingActivities": 148800,
"netChangeInCashAndCashEquivalents": -1677,
"cashAndCashEquivalentsBeginningOfPeriod": 14560,
"cashAndCashEquivalentsEndOfPeriod": 12883,
"supplementalCashFlowInformationCommonSharesIssuedForServices": 67400
},
"investmentsAndOtherAssets": [
{
"type": "Investment",
"description": "HHL (privately-held investment) - 1,696,032 common shares",
"ownershipPercentage": null,
"value": 101762,
"notes": "Acquired in February 2019. Fair value determined using Level 3 inputs (transaction price)."
},
{
"type": "Investment",
"description": "Port North Extracts Inc. units - 1,500,000 units (1 share + 1 warrant)",
"ownershipPercentage": null,
"value": 30000,
"notes": "Subscribed during year ended June 30, 2025. Fair value determined using Level 3 inputs (rent financing approach/transaction price)."
},
{
"type": "Investment",
"description": "Lophos Holdings Inc. shares",
"ownershipPercentage": null,
"value": 0,
"notes": "Received in exchange for HHL shares. Ceased trading, transferred to Level 3. Fair value $nil as at Dec 31, 2025."
}
],
"shareStructure": {
"authorizedShares": "unlimited",
"issuedShares": 435676173,
"classesOfShares": ["common shares"],
"warrants": [
{
"number": 28676064,
"exercisePrice": 0.2,
"expiryDate": "2026-01-12"
},
{
"number": 13050000,
"exercisePrice": 0.05,
"expiryDate": "2027-01-31"
},
{
"number": 16958714,
"exercisePrice": 0.05,
"expiryDate": "2027-02-26"
},
{
"number": 2900000,
"exercisePrice": 0.05,
"expiryDate": "2028-08-08"
},
{
"number": 3209523,
"exercisePrice": 0.05,
"expiryDate": "2028-08-08"
},
{
"number": 4352381,
"exercisePrice": 0.05,
"expiryDate": "2028-09-18"
}
],
"options": [
{
"number": 165000,
"exercisePrice": 0.28,
"expiryDate": "2027-04-10"
},
{
"number": 350000,
"exercisePrice": 0.07,
"expiryDate": "2029-12-27"
},
{
"number": 5100000,
"exercisePrice": 0.33,
"expiryDate": "2030-05-25"
},
{
"number": 9500000,
"exercisePrice": 0.35,
"expiryDate": "2026-06-21"
},
{
"number": 100000,
"exercisePrice": 0.6,
"expiryDate": "2026-07-19"
},
{
"number": 200000,
"exercisePrice": 0.6,
"expiryDate": "2026-08-10"
},
{
"number": 200000,
"exercisePrice": 0.6,
"expiryDate": "2026-08-16"
},
{
"number": 1000000,
"exercisePrice": 0.6,
"expiryDate": "2026-11-01"
},
{
"number": 200000,
"exercisePrice": 0.6,
"expiryDate": "2026-11-15"
},
{
"number": 100000,
"exercisePrice": 0.6,
"expiryDate": "2026-11-17"
},
{
"number": 150000,
"exercisePrice": 0.6,
"expiryDate": "2026-11-30"
},
{
"number": 5000000,
"exercisePrice": 0.05,
"expiryDate": "2029-01-02"
},
{
"number": 8300000,
"exercisePrice": 0.05,
"expiryDate": "2030-03-31"
},
{
"number": 1000000,
"exercisePrice": 0.05,
"expiryDate": "2030-08-12"
}
],
"rightsConvertibleInstruments": null
},
"managementCompensation": {
"currency": "CAD",
"periods": {
"threeMonthsEndedDec312025": {
"consultingFees": 229500
},
"sixMonthsEndedDec312025": {
"consultingFees": 229500
},
"threeMonthsEndedDec312024": {
"consultingFees": 60000
},
"sixMonthsEndedDec312024": {
"consultingFees": 180000
}
},
"namedIndividuals": [],
"otherRelatedPartyTransactions": [
{
"counterparty": "Marrelli Support Services Inc.",
"description": "CFO consulting and bookkeeping services",
"amount": 30146,
"period": "Six Months Ended December 31, 2025"
},
{
"counterparty": "DSA Corporate Services LP",
"description": "Corporate secretarial and filing services",
"amount": 14112,
"period": "Six Months Ended December 31, 2025"
},
{
"counterparty": "Marrelli Trust Company Limited",
"description": "Shareholder, transfer agent and corporate trustee services",
"amount": 2540,
"period": "Six Months Ended December 31, 2025"
}
]
},
"subsequentEvents": []
}
]
More from Revive Therapeutics Ltd
Jun 26, 2026 · 16:15